經(jīng)導(dǎo)管肝動(dòng)脈化療栓塞聯(lián)合局部注射無水乙醇治療中晚期原發(fā)性肝癌
無水乙醇,,無水乙醇；原發(fā)性肝癌；經(jīng)導(dǎo)管肝動(dòng)脈化療栓塞,1資料與方法,2結(jié)果,3討論,【參考文獻(xiàn)】
【摘要】 目的 探討經(jīng)導(dǎo)管肝動(dòng)脈化療栓塞(TACE)聯(lián)合經(jīng)皮注射無水乙醇(PEI)治療中晚期原發(fā)性肝癌的治療效果。方法 非隨機(jī)對(duì)照研究,納入90例中晚期原發(fā)性肝癌。41例接受TACE聯(lián)合PEI治療(治療組)，另49例僅接受TACE治療(對(duì)照組)。全部患者隨訪12個(gè)月，觀察安全性、局部治療效果及生存時(shí)間。結(jié)果 治療組患者共接受99次TACE、131次PEI治療，對(duì)照組共接受116次TACE治療。全部患者均無嚴(yán)重并發(fā)癥出現(xiàn)，治療組總有效率(CR+PR)高于對(duì)照組，分別是58.5%和28.6%(P<0.05)。治療組3、6、12個(gè)月生存率及生存曲線均高于對(duì)照組(P=0.0002)，兩組生存率分別為88.19%、75.03%、44.30%和62.12%、36.48%、21.02%，兩組差異有顯著性(P<0.05)。結(jié)論 本文研究結(jié)果提示經(jīng)導(dǎo)管肝動(dòng)脈化療栓塞聯(lián)合經(jīng)皮注射無水乙醇治療安全有效，提高了中晚期原發(fā)性肝癌的局部治療效果，延長(zhǎng)了患者的生存時(shí)間。【關(guān)鍵詞】 無水乙醇；原發(fā)性肝癌；經(jīng)導(dǎo)管肝動(dòng)脈化療栓塞
Transcatheter hepatic arterial chemoembolization in combination with percutaneous ethanol injection in patients with advanced primary hepatocellular carcinoma
LIU Yuan,GUAN Yongsong,HE Qing,et al.
Department of Radiology,West China Hospital,Sichuan University,Chengdu 610041，China
【Abstract】 Objective To evaluate the safety and efficacy of percutaneous ethanol injection (PEI) for the treatment of patients with advanced hepatocellular carcinoma (HCC) in combination with transcatheter hepatic arterial chemoembolization (TACE).Methods A total of 90 patients with advanced HCC were enrolled in a nonrandomized clinical trial.Of which,49 were treated only by transcatheter hepatic arterial chemoembolization (control group) while the other 41 received a combination treatment of TACE and PEI (treatment group).Patients were followed up for 12 months and the safety,therapeutic effects and survival time were evaluated and analysed statistically.Results A total of 116 procedures of TACE in control group,131 procedures of PEI and 99 procedures of TACE in treatment group were performed respectively.No serious complication was identified.The total effective rates (CR+PR) of the treatment group and the control group were 58.5% and 28.6% respectively (P<0.05).The survival rates at 3 months (mo),6 mo and 12 mo were 88.19%,75.03% and 44.30% in the treatment group and 62.12%,36.48% and 21.02% in the control group,respectively,which suggested significantly better survival rates in the treatment group compared to the control group (P=0.0002).Conclusion The data from this clinical trial suggest that the combination treatment of PEI and TACE is safe and feasible and can improve local antitumor efficacy and survival time for patients with advanced HCC. ......
您現(xiàn)在查看是摘要頁，全文長(zhǎng) 10943 字符。